Edward R Mariano, MD, MAS

home / authors / edward-r-mariano-md-mas

Articles

A Perioperative Pain Management Expert Checks His Crystal Ball for the Look of the Practice in 2050

A Perioperative Pain Management Expert Scans His Crystal Ball for the Look of the Practice in 2050

February 13th 2025

More consistent use of evidence-based guidelines and individualized pain management for every patient lead the hopes Edward Mariano, MD, MAS has for the future.

Overlap in Pathophysiology Suggests New Approaches to Acute Pain May Transfer to Relief from Chronic Pain: A Closer Look

Edward R Mariano, MD, MAS;Grace Halsey

February 12th 2025

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.

Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS

Edward R Mariano, MD, MAS;Grace Halsey

February 11th 2025

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

Use of Perioperative Multimodal Pain Management in the US Remains Low, Expert Says

Edward R Mariano, MD, MAS;Grace Halsey

February 10th 2025

An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.

Opioid Prescribing Has Come a Long Way, According to Stanford Pain Expert Edward Mariano, MD, MAS

Edward R Mariano, MD, MAS;Grace Halsey

February 6th 2025

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.

Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action

Edward R Mariano, MD, MAS;Grace Halsey

January 31st 2025

Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.